Rituximab as a treatment option for refractory endogenous anterior uveitis
Options
BORIS DOI
Publisher DOI
PubMed ID
17534119
Description
BACKGROUND
To report on anti-CD20 antibody therapy in a patient with uveitis refractive to immunosuppression therapy.
METHODS
Case report with ophthalmoscopic, optical coherence tomography and fluorescein-angiographic findings.
RESULTS
A 49-year-old woman was suffering from bilateral, noninfectious chronic anterior uveitis refractive to corticosteroids and immunosuppressive drugs. Bilateral visual acuity was 20/100 due to cataract and cystoid macular edema (CME). After treatment with rituximab, vision and CME improved, and uveitis was stable until the final visit (follow-up at 12 months).
CONCLUSION
The case report suggests that rituximab may be helpful for selected patients with chronic anterior uveitis refractive to corticosteroids and immunosuppressive medication.
To report on anti-CD20 antibody therapy in a patient with uveitis refractive to immunosuppression therapy.
METHODS
Case report with ophthalmoscopic, optical coherence tomography and fluorescein-angiographic findings.
RESULTS
A 49-year-old woman was suffering from bilateral, noninfectious chronic anterior uveitis refractive to corticosteroids and immunosuppressive drugs. Bilateral visual acuity was 20/100 due to cataract and cystoid macular edema (CME). After treatment with rituximab, vision and CME improved, and uveitis was stable until the final visit (follow-up at 12 months).
CONCLUSION
The case report suggests that rituximab may be helpful for selected patients with chronic anterior uveitis refractive to corticosteroids and immunosuppressive medication.
Date of Publication
2007
Publication Type
Article
Subject(s)
Language(s)
en
Contributor(s)
Heinz, Carsten | |
Specker, Christof | |
Heiligenhaus, Arnd |
Additional Credits
Series
Ophthalmic research
Publisher
Karger
ISSN
0030-3747
Access(Rights)
open.access